Latest Janus kinase inhibitor Stories
FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS INDIANAPOLIS, Dec.
-Significant synergy resulted with combination treatment of pacritinib and cytarabine or a MEK inhibitor- SEATTLE, Dec. 9, 2014 /PRNewswire/ -- CTI BioPharma Corp.
-Profile Supports Potential Role in Modulating Tumor Microenvironment in Blood-Related Cancers, Including AML, MDS, CMML and CLL- SEATTLE, Dec.
SEATTLE, Dec. 1, 2014 /PRNewswire/ -- CTI BioPharma Corp.
SEATTLE, Aug. 7, 2014 /PRNewswire/ --CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that pacritinib has been granted Fast Track designation by the U.S.
-Top-line Results Expected in Early 2015- SEATTLE, July 1, 2014 /PRNewswire/ -- CTI BioPharma Corp.
- This Trial, Together with PERSIST-1, to Support Registration in the U.S. and Europe - SEATTLE, March 3, 2014 /PRNewswire/ -- Cell Therapeutics, Inc.
- Trial Sponsored by Cardiff University and Supported by Cancer Research UK - SEATTLE, Jan. 30, 2014 /PRNewswire/ -- Cell Therapeutics, Inc.
- A gift; a largess; a gratuity; a present; a dole.